# DESCRIPTION

## STATEMENT OF GOVERNMENT INTEREST

- acknowledge government support

## BACKGROUND OF THE INVENTION

- introduce myocardial infarction
- discuss limitations of current hydrogels
- highlight advantages of self-assembling peptides

## SUMMARY OF THE INVENTION

- introduce cyclic peptide composition
- describe method of use for treating tissues
- outline embodiments of composition and method

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate by reference

### Definitions

- define articles
- define "comprising", "including", and "having"
- define "and/or"
- define "consisting" and "consisting essentially of"
- define range format
- define "about"
- define "patient" or "subject"
- define "pharmaceutical composition"
- define "pharmaceutically acceptable"
- define "pharmaceutically acceptable carrier"
- define "therapeutically effective"
- define "treatment"
- describe conventional techniques
- describe self-assembling peptides
- describe cyclic peptides
- describe substrate recognition sequence
- describe MMP-2/9 cleavable sequence
- describe peptide labeling and detection

## EXAMPLES

- introduce cyclic peptide progelators
- enzymatic cleavage of progelators
- design of stimuli-responsive SAPs
- self-assembly of SAPs
- modification of SAP sequences
- prediction of SAP assembly
- experimental validation of SAP assembly
- cyclization and progelator formulation
- characterization of cyclic progelators
- responsiveness of progelators to inflammation-associated enzymes
- assembly of viscoelastic and rehealable hydrogels
- simulation of in vivo environment
- catheter compatibility of cyclic peptide progelators
- minimally invasive injection of hydrogels
- hemocompatibility of cyclic progelator
- in vivo gelation in a rat myocardial infarction model
- assessment of thrombogenic response
- demonstrate progelator in vivo
- describe platform modification strategy
- motivate SAPs for biomedical applications
- summarize in silico modeling results
- describe experimental analysis of self-assembly characteristics
- demonstrate versatility of platform
- describe development of smart structurally dynamic materials
- assess hemocompatibility and thrombogenicity
- describe general information and materials
- outline peptide synthesis and purification
- describe mass spectrometric analysis of peptides
- describe UV absorbance spectra and progelator sterilization
- describe transmission electron microscopy (TEM)
- describe static and dynamic light scattering (SLS and DLS)
- describe experimental circular dichroism (CD)
- describe computational modeling with FibPredictor
- describe theoretical CD spectra with DichroCalc
- describe in vitro enzyme cleavage of cyclic peptide progelator
- describe rheological characterization
- describe in vitro catheter injections and effect on assembly
- describe hemocompatibility analysis
- describe activated clotting times (ACT) with whole human blood
- describe whole blood hemostasis kinetics
- describe hemolysis assay
- describe pro-thrombotic assays
- describe in vivo studies
- describe cryo-sectioning, histology, and immunofluorescence imaging
- describe statistical analysis

